IL-15-based molecules and methods of use thereof

Patent metadata

Field	Value
Publication number	US-11173191-B2
Application number	US-201916444807-A
Country	US
Kind code	B2
Filing date	Jun 18, 2019
Priority date	Jun 30, 2014
Publication date	Nov 16, 2021
Grant date	Nov 16, 2021

Abstract

The invention features combination therapies using an IL-15-based superagonist complex and an antibody to effectively treat subjects with cancer and infectious diseases.

First claim

What is claimed is:

1. A method of treating cancer, comprising: administering to a human subject in need thereof i) an effective amount of Bacillus Calmette-Guerin (BCG) and ii) an effective amount of an IL-15N72D:IL-15RαSu/Fc complex.

2. The method of claim 1 wherein the subject has bladder cancer.

3. The method of claim 1 wherein the subject has non-muscle invasive bladder cancer (NMIBC).

4. The method of claim 1 wherein the subject has BCG-naive non-muscle invasive bladder cancer.

5. The method of claim 1 wherein the IL-15N72D:IL-15RαSu/Fc complex comprises a dimeric IL-15RαSu/Fc and two IL-15N72D molecules.

6. The method of claim 1 wherein ALT-803 is administered to the subject.

7. The method of claim 1 wherein ALT-803 in combination with BCG is administered by instillation into the bladder of the subject.

8. The method of claim 1 wherein the subject has been identified as suffering from non-muscle invasive bladder cancer (NMIBC).

Assignees

• Altor Bioscience Llc

Inventors

• Liu Bai
• Rhode Peter
• Xu Wenxin
• Wong Hing C

Classifications

• C07K2319/32

  fusions with soluble part of a cell surface receptor, "decoy receptors" · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61K38/1793

  for cytokines; for lymphokines; for interferons · CPC title

• A61K39/39558

  against tumor tissues, cells, antigens · CPC title